Reach of Community-Selected Strategies to Reduce Opioid-Related Overdose Deaths in the HEALing Communities Study
Authors:
Open Access
- 2 September 2025
- journal article
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 61 (2) , 200-208
Abstract
Despite recent declines, the U.S. opioid overdose crisis persists. The HEALing Communities Study (HCS) aimed to reduce opioid overdose deaths through community-level adoption of evidence-based practices (EBPs), including overdose education and naloxone distribution (OEND) and medications for opioid use disorder (MOUD). This paper describes the reach of OEND and MOUD strategies implemented by the 33 HCS wait-list control communities. We conducted descriptive statistical analysis of reach data collected from July 2022 through December 2023 to (1) summarize overall EBP implementation and reach and (2) compare the demographic representation of individuals reached to community demographic population estimates. Communities implemented 474 EBPs (251 OEND, 223 MOUD), reporting an average reach of 16,482 individuals monthly. For OEND, percent reached exceeded community population representation for individuals aged 18-34 years (40% vs 31%) and 35-54 years (41% vs 31%) and non-Hispanic Black individuals (20% vs 15%). For MOUD, percent reached exceeded the opioid use disorder population representation for individuals aged 35-54 years (58% vs 52%) and non-Hispanic White individuals (88% vs 80%); however, there was lower representation for individuals aged 18-34 years (28% vs 38%) and non-Hispanic Black individuals (6% vs 13%). Distributions by sex were comparable for OEND and MOUD. Findings signal the promise of community-engaged interventions to reach diverse groups with OEND and reflect the challenges of overcoming longstanding barriers to MOUD access. This work provides practical examples for monitoring the reach of EBPs across multiple research sites and communities and for assessing representativeness, a valuable marker of equity. Trial Registration: Clinical Trials.gov http://www.clinicaltrials.gov: Identifier: NCT04111939.Keywords
Funding Information
- National Institute on Drug Abuse (UM1DA049394)
This publication has 44 references indexed in Scilit:
- Addressing Racial and Ethnic Inequities in Opioid Overdose Mortality: Strategies for Equitable Interventions and Structural ChangeCurrent Psychiatry Reports, 2024
- Racial and Ethnic Disparities in Buprenorphine Treatment Duration in the USJAMA Psychiatry, 2023
- Racial and Ethnic Disparities in Drug Overdose Deaths in the US During the COVID-19 PandemicJAMA Network Open, 2022
- Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018JAMA Health Forum, 2022
- Geographic Trends in Opioid Overdoses in the US From 1999 to 2020JAMA Network Open, 2022
- Evaluation of Increases in Drug Overdose Mortality Rates in the US by Race and Ethnicity Before and During the COVID-19 PandemicJAMA Psychiatry, 2022
- Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United StatesJAMA Network Open, 2020
- Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid AddictionJournal of General Internal Medicine, 2019
- Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine TreatmentThe Journal of Behavioral Health Services & Research, 2018
- Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependenceCochrane Database of Systematic Reviews, 2014